A look at the AI chatbots designed to improve mental health, like Wysa and Woebot, which have millions of users despite scant research to support their efficacy
Context & Ripple Effects
This 2022 Wired piece is the early marker in an arc the corpus keeps extending: Wysa and Woebot had already reached millions of users while the research base lagged far behind adoption. What followed only widened the gap — by 2023 people were using chatbots as a supplement to, or substitute for, traditional therapy despite privacy concerns, and by 2024 free-to-use bots were marketing themselves to teenagers with experts still split on whether they work at all.
First-order effects
- Millions of Wysa and Woebot users are receiving mental-health support whose efficacy is largely unvalidated, while the products' appeal — cheap, always available, easy to talk to — keeps pulling demand ahead of the evidence.
Second-order effects
- Clinicians are forced to respond inside their own practices: by 2026, interviews with over 100 therapists and psychiatrists found client chatbot use sometimes deepening negative feelings, and eating-disorder specialists report patients using bots in ways that undermine treatment advice.
Third-order effects
- If adoption keeps outrunning validation, the likely endpoint is governance pressure — efficacy standards, safety rules, or disclosure requirements for companion-style health AI — rather than the market self-correcting through research.
The trend: Consumer mental-health AI is scaling on distribution and availability faster than clinical evidence or regulation can validate it, making efficacy the unresolved fault line of the category.